Drug Profile
Research programme: iPSC derived engineered T cell immunotherapies - Fate Therapeutics/Ono Pharmaceuticals
Alternative Names: CAR targeted, TCR-null CD8αβ+ T cells; FT 8xx; FT-ONO1; FT-ONO2; FT817; FT896; FT8solid; TCRless + TRAC-CARsolid + USE; TCRless TRAC-Targeted CAR-BCMA; TCRless TRAC-Targeted CAR19 + USELatest Information Update: 01 Jul 2022
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Fate Therapeutics; Ono Pharmaceutical
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 28 Jun 2022 Fate Therapeutics expanded development and commercialisation agreement with ONO Pharmaceutical for the development of CAR NK and CAR T-celll cancer immunotherapies in
- 11 Jan 2022 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in USA, Japan (Parenteral) (Fate Therapeutics pipeline, January 2022)
- 05 Dec 2020 Pharmacodynamics data from preclinical studies presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)